AIP
TVTX icon

Arrowpoint Investment Partners’s Travere Therapeutics TVTX Stock Holding History

Arrowpoint Investment Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.13M Buy
+55,112
New +$2.44M 0.68% 25

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowpoint Investment Partners's TVTX Position: Q2 2026 in Review

Arrowpoint Investment Partners opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 55,112 shares worth $3.13M. The stake represents 0.68% of the portfolio and ranks #25 among its holdings.

320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Arrowpoint Investment Partners held 55,112 shares of Travere Therapeutics worth $3.13M as of Q2 2026.
  • Travere Therapeutics was a new Arrowpoint Investment Partners position in Q2 2026.
  • Travere Therapeutics made up 0.68% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #25 holding.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.